"With an 80-year history and a team of more than 1,200 healthcare professionals, Miami Jewish Health has been built with a focus on tomorrow, providing access to the latest research trials, offering a comprehensive line of health services, living facilities and programs, and employing an innovative care model centered on empathy."

During the past decade, Miami Jewish Health Systems conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 19 clinical trials were completed, i.e. on average, 47.5% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 12 clinical trials were completed. i.e. 92.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Miami Jewish Health Systems" #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Biogen" with 4 trials sponsored, "Genentech, Inc." with 4 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 4 trials sponsored and "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 4 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Miami Jewish Health Systems" #1 collaborator was "National Institute on Aging (NIA)" with 6 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Alzheimer's Association" with 2 trials as a collaborator, "Biogen" with 2 trials as a collaborator and "Alzheimer's Therapeutic Research Institute" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Miami Jewish Health Systems" are "Alzheimer's Disease" (23 trials), "Alzheimer Disease" (12 trials), "Mild Cognitive Impairment" (4 trials), "Agitation in Patients With Dementia of the Alzheimer's Type" (3 trials) and "Dementia" (2 trials). Many other conditions were trialed in "Miami Jewish Health Systems" in a lesser frequency.

Most popular intervention types in "Miami Jewish Health Systems" are "Drug" (48 trials), "Other" (6 trials), "Biological" (2 trials), "Device" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "AVP-786" (3 trials), "Placebo Control" (3 trials), "[18F]GTP1" (3 trials) and "Bapineuzumab 0.5 mg/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Miami Jewish Health Systems" are 55 trials for "All" genders.

Currently, there are NaN active trials in "Miami Jewish Health Systems". 1 are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 30 completed trials in Miami Jewish Health Systems, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Miami Jewish Health Systems, 7 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".